The University of Oxford conducted a study recently in collaboration with a handful of other UK research centers all supported by the UK Coronavirus Immunology…
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the acquisition of Tissue Solutions Ltd., a virtual biobank…
Thanks to a £6.8m ($9.3m) award from the National Institute of Health Research (NIHR), University College London Hospitals NHS Foundation Trust (UCLH) and University College…
The United Kingdom (UK) continues to operate at the top of the life science pyramid with the success of its life science sector, particularly with…
Three major biopharmaceutical companies came together to facilitate a generic exome sequence analysis collaboration paving the way to offering the world’s largest browsable resource linking…
Vaccine developer Novavax, Inc. (Nasdaq: NVAX) recently announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of its COVID-19…
Back in January 2021, TrialSite reported that the University of Oxford was “considering” ivermectin for its PRINCIPLE clinical trial or the “Platform Randomized Trial of Treatments…
Article 1 | UK-based Meta Analysis Peer Reviewed & Published Suggests Ivermectin A Key Public Health Weapon in the War Against COVID-19:Recently published in the…
TrialSite calls attention to Alex Keown’s recent article showcasing the recent meta-analysis published in the American Journal of Therapeutics indicating that ivermectin as a potential treatment…
Recently, the British press featured a story centering on prominent research involved with the Oxford Vaccine Group, a key player in the development of the…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
